PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-939

No spruiking required , up until 26 months ago the Company was solely focused on Oncology with a slight interlude for 22 months of Covid Testing and Trialing in multiple countries..

The recent success of PAA utilising MPL for the Treatment of Neurological Diseases / Disorders is only adding to already existing Value and Credibility. NZT
Which is ideal as Covid lifted the SP to 26c previously as MPL delivered Positive Results on every single trial at 3 independent Research Facilities.

Just because something is not currently front and centre or under the microscope does not negate its Value... for those on RAC Bisantrene the lead drug was left over from a larger takeover of a firm where the lead drug was the sole focus of the Purchaser ,Biseantrene was left in the cupboard ,, RAC purchased it ,was up at $500m MC currently at $290m.

K9 , well Aratana was purchased for a K9 Lymphoma Treatment for $245m by Elanco ,,,

So the IP in the cupboard currently at PAA doesn't need spruiking , those that know the History Know the Value,,, NZT